Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02721056
Recruitment Status : Active, not recruiting
First Posted : March 28, 2016
Last Update Posted : October 6, 2020
Sponsor:
Information provided by (Responsible Party):
Nanobiotix

Brief Summary:
The purpose of this Phase I / II study is to evaluate the safety and preliminary efficacy of NBTXR3 nanoparticles given by intralesional (IL) or intraarterial (IA) injection and activated by Stereotactic Body Radiation Therapy in the treatment of liver cancers.

Condition or disease Intervention/treatment Phase
Liver Cancer Radiation: NBTXR3, IL or IA injection + SBRT Phase 1 Phase 2

Detailed Description:

PHASE I PART: Dose escalation and Recommended Dose (Volume) The purpose of the Phase I part of the study is to determine the Recommended Dose (volume), the safety profile and the feasibility of the treatment of NBTXR3 administered either by intrahepatic lesion injection or super selective transcatheter arterial injection and activated by stereotactic body radiation therapy (SBRT), in patients with liver cancers. Primary objective

- To determine the Recommended Dose(s) (volume(s)) and the early Dose Limiting Toxicity (DLT) of NBTXR3 administered either by intralesional injection or by super selective transcatheter arterial injection and activated by stereotactic body radiation therapy (SBRT) in patients with liver cancers

PHASE II PART: Safety and Efficacy evaluation Primary objectives

The primary objectives of the Phase II part are:

  • To assess and characterize the safety profile, including liver function evaluation using MELD/MELD-Na and Child-Pugh scores, of NBTXR3 activated by SBRT, at the Recommended Dose(s)(Volume(s)) as determined previously in the Phase I part, in patients with liver cancers Clinical Investigation Plan - NBTXR3/103
  • To evaluate the antitumor activity in terms of Complete Response Rate (CRR) of target lesions, as per mRECIST for HCC and RECIST version 1.1 for liver metastases at 12 weeks' post radiotherapy, of NBTXR3 activated by SBRT, at the Recommended Dose(s) (Volume(s)) as determined previously in the Phase I part, in patients with liver cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I-II Study of NBTXR3 Activated by Sterostatic Body Radiation Therapy (SBRT) In the Treatment of Liver Cancers
Actual Study Start Date : January 15, 2016
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : September 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Cancer

Arm Intervention/treatment
Experimental: NBTXR3, IL or IA injection +SBRT
  • Patients will receive a single intralesional (IL) injection of NBTXR3 at four increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, 33% and 42% of the baseline tumor volume, activated by SBRT.
  • Patients with primary and secondary nodular intra hepatic cancers only will receive a single superselective transcatheter arterial (IA) injection of NBTXR3 at five increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, 33% and 45% of the baseline tumor volume, activated by SBRT.
Radiation: NBTXR3, IL or IA injection + SBRT
Patients will receive a single administration of NBTXR3 on day of injection, as intralesional or super selective transcatheter arterial injection activated by Stereotactic Body Radiation Therapy starting 24 hours post injection. The total radiotherapy dose will be 45 or 50 Gy, delivered as three fractions of 15 Gy or 5 fractions of 10 Gy each, over 5 to 15 days (45 or 50Gy, 15GyX3 or 10GyX5).




Primary Outcome Measures :
  1. Determination of the Recommended Doses Toxicities (DLT) [ Time Frame: 50 Months ]
    To determine the Recommended Doses (DLT) of NBTXR3 administered as two different schedules (intra-lesional or intra-arterial injection), activated by Stereotactic Body Radiation Therapy (SBRT)

  2. Determination of the early Dose Limiting Toxicities [ Time Frame: 50 Months ]
    To determine the early Dose Limiting Toxicities


Secondary Outcome Measures :
  1. Number of patients with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 50 Months ]
  2. Response Rate [ Time Frame: 50 Months ]
    To evaluate the antitumor activity in terms of Response Rate (RR) of target lesions/s, as per mRECIST and RECIST 1.1 criteria

  3. Local Progression Free Survival [ Time Frame: 50 Months ]
    To evaluate the local control in terms of local Progression Free Survival



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Secondary cancer, Liver metastases

Inclusion criteria:

  • Age ≥ 18
  • Written Informed Consent obtained, signed and dated
  • ECOG performance status 0 or 1
  • Life expectancy > 6 months
  • Liver metastases from other primary cancers 1) with histologic confirmation of metastases, or 2) History of primary cancer with histology available and lesions in the liver consistent with metastases, or 3) histologic confirmation of primary cancer and a growing enhancing lesion in the liver consistent with a metastasis
  • Unresectable tumor/s, based on the opinion of an experienced surgeon specializing in hepatic resection, or the patient must be medically inoperable
  • Patients with extra-hepatic metastases controlled by supportive care or concomitant hormonotherapy are eligible.
  • Previous liver resection or local treatment (radiofrequency ablative therapy, chemoembolization, microwave treatment…) is permitted
  • Patients must have recovered from the effects of previous therapy (residual AE grade 0 or 1)
  • Radiological disease progression according to the investigator evaluation or according to RECIST 1.1
  • At least one tumor lesion that can be accurately measured in at least one dimension according to RECIST 1.1
  • Normal permeability of hepatic artery evaluated by injected CT-scan (arterial phase)
  • Total target volume of lesions < 500cc and < 50% of the total liver volume
  • 700 cc of liver volume without tumor involvement and a radiation therapy dose < 15 Gy
  • The following laboratory parameters:
  • Platelet count ≥ 50 x 10^9/L
  • Hemoglobin ≥ 8.5 g/dL
  • Absolute neutrophil count ≥ 1.5 x 10^9/L,
  • Prothrombin rate (PR)> 50%
  • International Normalized Ratio (INR) < 1.5 or correctable with vitamin K. Patients receiving anti-coagulation or anti-aggregation therapy must stop temporarily during treatment.
  • Total bilirubin <30 μmol/l
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x upper limit of normal
  • Albumin >2.5 g/dL
  • Very low or undetectable HBV DNA and HCV RNA
  • Serum Creatinine ≤ 1.5 time the upper limit of normal value
  • Glomerular Filtration Rate > 44mL/min/1.73m2
  • All female patients of childbearing potential must have a negative serum/urinary pregnancy test within the 7 days prior to NBTXR3 administration. Otherwise, Patients must be post-menopausal, surgically sterile, or using 'effective contraception'. The definition of 'effective contraception' will be based on the judgment of the investigator.

Exclusion criteria:

  • Patients with ongoing chronic active viral B or C hepatitis must have received an antiviral treatment with negative or very low viremia before the onset of the radiation therapy
  • Biliary tract dilatation, biliodigestive anastomosis, bile duct drainage
  • Uncontrolled extra-hepatic metastatic disease with a symptomatic treatment or well tolerated hormonotherapy (AE 0/1)
  • Previous cancer cured for less than 2 years
  • Previous anticancer treatment (chemotherapy or/and biologicals) with a wash out < 4 weeks
  • Previous treatment with intra-arterial injection of Y90 loaded microspheres in the same hepatic lobe than the current tumor.
  • Previous intra-arterial chemotherapy
  • Prior radiation therapy to the right upper abdomen, precluding re-irradiation of the liver. That is, any previous radiation therapy in which a mean dose to the liver of 15 Gy in conventional fractionation was delivered, or previous doses to critical normal structures that would make re-irradiation unsafe
  • Impossibility to follow the dosimetry constraints (mean total liver dose > 15Gy)
  • Presence of arterio-venous intra tumoral shunting
  • Encephalopathy related to liver failure
  • Clinical ascitis
  • Presence of another scalable tumor disease except cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors (Ta, Tis &T1)
  • Presence of hepato pulmonary syndrome
  • Auto immune hemolytic anemia
  • Auto immune disorder, excepted auto immune thyroiditis
  • Uncontrolled hypertension or congestive heart failure
  • Active coronary artery disease (myocardial infarction more than 6 months prior to study entry is permitted)
  • Previous gastrointestinal bleed within the past 2 months
  • Known syndrome AIDS-related illness or serious non controlled acute or chronic illness
  • Active, clinically severe bacterial or fungal infections (> grade 2 NCI-CTCAE, version 5.0)
  • Complete initial work up earlier than 4 weeks prior to patient registration
  • Patient whose general health condition does not allow treatment feasibility
  • Patients unable and/or unwilling to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
  • Patients participating in another clinical investigation at the time of signature of the informed consent.

Primary cancer: Hepato Cellular Carcinoma - HCC

Inclusion criteria:

  • Age ≥ 18
  • Written Informed Consent obtained, signed and dated
  • ECOG performance status 0 or 1
  • Life expectancy > 3 months
  • Histological or cytological diagnosis of Hepatocellular cancer or imaging diagnosis by the American Association for the Study of Liver Disease (AASLD) guidelines or European association for the Study of the Liver (EASL) guidelines.
  • Patients with HCC:
  • Without main branch or intrahepatic trunk portal vein tumor thrombosis (Vp3 or Vp4, respectively), with progression or recurrence of HCC after surgical or loco-regional treatment
  • With main branch (right and/or left) or intrahepatic trunk portal vein tumor thrombosis (Vp3 or Vp4, respectively), AND without right atrial involvement.
  • Recurrent intrahepatic cholangiocarcinoma is eligible only in the phase I part
  • Liver cirrhosis Child Pugh A - B7
  • Previous liver resection or local treatment (radiofrequency ablative therapy, chemoembolization, microwave treatment…) is permitted
  • Patients with previous treatment with sorafenib or other targeted or systemic therapy are eligible if wash out > 4 weeks
  • Patients must have recovered from the effects of previous therapy (residual AE grade 0 or 1)
  • Radiological disease progression according to the investigator evaluation or according to RECIST 1.1
  • At least one tumor lesion that can be accurately measured in at least one dimension according to RECIST 1.1
  • Normal permeability of hepatic artery evaluated by injected CT-scan (arterial phase)
  • Total target volume of lesions < 500cc and < 50% of the total liver volume
  • 700 cc of liver volume without tumor involvement and a radiation therapy dose < 15 Gy
  • The following laboratory parameters:
  • Platelet count ≥ 50 x 10^9/L
  • Hemoglobin ≥ 8.5 g/dL
  • Absolute neutrophil count ≥ 1.5 x 10^9/L,
  • Prothrombin rate (PR)> 50%
  • International Normalized Ratio (INR) < 1.5 or correctable with vitamin K
  • Patients receiving anti-coagulation or anti-agregant therapy must stop temporarily during treatment.
  • Total bilirubin <30 μmol/l
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x upper limit of normal
  • Albumin >2.5 g/dL
  • Very low or undetectable HBV DNA and HCV RNA
  • Serum Creatinine ≤ 1.5 time the upper limit of normal value
  • Glomerular Filtration Rate > 44mL/min/1.73m2
  • All female patients of childbearing potential must have a negative serum/urinary pregnancy test within the 7 days prior to NBTXR3 administration. Otherwise, Patients must be post-menopausal, surgically sterile, or using 'effective contraception'. The definition of 'effective contraception' will be based on the judgment of the investigator.

Exclusion criteria:

  • Patient suitable for a curative treatment by surgery or local treatment (radiofrequency ablation, microwave treatment, etc.)
  • Patients with ongoing chronic active viral B or C hepatitis, those patients must have received an antiviral treatment with negativation of the viremia or very low viremia before the onset of the radiation therapy
  • Biliary tract dilatation, biliodigestive anastomosis, bile duct drainage
  • Extrahepatic Portal Vein Tumor Thrombosis
  • Extra-hepatic metastasis
  • Previous cancer cured for less than 2 years
  • Previous anticancer treatment (chemotherapy or/and biologicals) with a wash out < 4 weeks
  • Previous treatment with intra-arterial injection of Y90 loaded microspheres in the same hepatic lobe than the current tumor.
  • Previous intra-arterial chemotherapy
  • Concurrent treatment with any other anticancer therapy, including chemotherapy, immunotherapy, targeted therapy, gene therapy, or patients planning to receive these treatments during the study. Hormonotherapy is permitted
  • Prior radiation therapy to the right upper abdomen, precluding re-irradiation of the liver. That is, any previous radiation therapy in which a mean dose to the liver of 15 Gy in conventional fractionation was delivered, or previous doses to critical normal structures that would make re-irradiation unsafe
  • Impossibility to follow the dosimetry constraints (mean total liver dose > 15Gy)
  • Presence of arterio-venous intra tumoral shunting
  • Encephalopathy related to liver failure
  • Clinical ascitis
  • Presence of another scalable tumor disease except cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors (Ta, Tis &T1)
  • Presence of hepato pulmonary syndrome
  • Auto immune hemolytic anemia
  • Auto immune disorder, excepted auto immune thyroiditis
  • Uncontrolled hypertension or congestive heart failure
  • Active coronary artery disease (myocardial infarction more than 6 months prior to study entry is permitted)
  • Previous gastrointestinal bleed within the past 2 months
  • Known syndrome AIDS-related illness or serious non- controlled acute or chronic illness
  • Active, clinically severe bacterial or fungal infections (> grade 2 NCI-CTCAE, version 5.0)
  • Complete initial work up earlier than 4 weeks prior to patient registration
  • Patient whose general health condition does not allow treatment feasibility
  • Patients unable and/or unwilling to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
  • Patients participating in another clinical investigation at the time of signature of the informed consent. Phase I and II parts target the same liver cancer populations (same inclusion and

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02721056


Locations
Layout table for location information
France
CHU La Croix Rousse
Lyon, France, 69004
Institut de Cancérologie de Loraine
Nancy, France, 54500
CHU de NANCY
Nancy, France, 54511
Centre René Gauducheau
Nantes, France, 44805
Hôpital Haut-Lévêque
Pessac, France, 33604
Centre Eugène Marquis
Rennes, France, 35000
Institut Gustave Roussy
Villejuif, France, 94800
Sponsors and Collaborators
Nanobiotix
Layout table for additonal information
Responsible Party: Nanobiotix
ClinicalTrials.gov Identifier: NCT02721056    
Other Study ID Numbers: NBTXR3-103
First Posted: March 28, 2016    Key Record Dates
Last Update Posted: October 6, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Liver Diseases